Roche Cipla Medical Cocktail Promises Covid-19 Mortality Drop-In India
Cipla has a new card up its sleeve. As the pandemic has opened the market for home deliveries and meal services, it is also becoming a marketing opportunity for immunity boosters and energy drinks as well. The new kid on the block costs Rs. 59750 per dose and is called Roche’s antibody cocktail.
Apparently, this will work well for mild to moderately affected Covid-19 patients, who might be at high risk due to underlying diseases.
Brought out jointly by Roche and Cipla in India, the cocktail will comprise Casirvimab and Imdevimab and is being made available. The second batch will be made available in mid-June. According to an official joint statement, the cocktail will potentially benefit two million patients as each of the one million packs are going to be available in India will cater to two patients together.
Apparently, the maximum retail price of the two drugs put together is being estimated at Rs. 1.20 lakhs (inclusive of all taxes).
Cipla intends to use its large marketing base to distribute this cocktail drug which is going to be available in leading hospitals and Covid centers too. Apparently, the drug cocktail is going to reduce the pressure off hospitals and will (hopefully) bring down the death rate in India.
Apparently, the drug cocktail has received an emergency approval from the Central Drugs Standards Control Organisation (CDSCO). Similar approvals have come through EUA in the US and several other European countries as well.
The cocktail will work well on children above the age of 12 years and 40 kgs or more, with no other underlying diseases and who not require oxygenation either. According to an official statement by Cipla, the medical cocktail is said to have reduced the risk of hospitalization and fatality by 70 percentage and has shortened the duration of the symptoms by four days.
One can only hope that the medicine cocktail does not start off another racket of black marketing and misuse in the country.